Collagen-related peptides and uses thereof

1. A composition comprised of a collagen-related peptide of Formula (I):

B-(Z) m -X

wherein

Z is selected from the group consisting of Gly-Pro-J, Pro-J-Gly and J-Gly-Pro;

J is selected from the group consisting of Hyp, fPro, mPro and Pro;

m is an integer selected from 8, 9, 10, 11, 12, 13, 14 or 15; and,

B and X are independently selected from the group consisting of F 5 -Phe, Phe wherein the phenyl ring is mono or disubstituted with fluoro, chloro, bromo, hydroxyl, methyl or CF 3 , Tyr, 3,4-(OH) 2 -Phe, MeO-Tyr, phenylglycine, 2-naphthyl-Ala, 1-naphthyl-Ala, Trp, Cha, Chg, Met, Leu, Ile and Val,

wherein the composition is in the form of a foam, a powder, a fiber, or a film, wherein the composition comprises a plurality of said collagen-related peptides, wherein the collagen-related peptides are present in the form of a plurality of collagen-related peptide trimers, and wherein the collagen-related peptide trimers are homotrimers or heterotrimers.

2. The composition of claim 1 , wherein the composition is in the form of a foam and further comprises, based upon the total dry weight of the foam, from about 0.1 percent to about 15 percent of a plasticizer.

3. The composition of claim 2 , wherein the plasticizer is selected from the group consisting of glycerol; polyethylene glycol; glycerin; propylene glycol; monoacetate of glycerol; diacetate of glycerol; triacetate of glycerol; and mixtures thereof.

4. The composition of claim 1 , wherein the composition is in the form of a foam having a thickness of about 0.5 mm to about 10 mm.

5. The composition of claim 1 , wherein the composition is in the form of a foam having a pore size of from about 1 micron to about 500 microns.

6. The composition of claim 1 , wherein the composition is in the form of a film having a thickness of about 50 microns to about 150 microns.

7. The composition of claim 1 , wherein the composition is in the form of a powder and the powder has a particle size of about 1 micron to about 2000 microns.

8. The composition of claim 7 further comprising a carrier selected from polysaccharides; mannitol; porous lava; polyesters; and copolymers and mixtures thereof.

9. The composition of claim 8 , wherein the polysaccharide is selected from the group consisting of starch; pectin; cellulose; alkyl cellulose wherein the alkyl group has from about 1 to about 7 carbon atoms; alkylhydroxyalkyl cellulose wherein the alkyl group has from about 1 to about 7 carbon atoms; hydroxyalkyl cellulose wherein the alkyl group has from about 1 to about 7 carbon atoms; cellulose sulfate; salts of carboxymethyl cellulose; carboxymethyl cellulose; carboxyethyl cellulose; chitin; carboxymethyl chitin; hyaluronic acid; salts of hyaluronic acid; alginate; cross-linked alginate; alginic acid; propylene glycol alginate; glycogen; dextran; dextran sulfate; curdlan; pectin; pullulan; xanthan; chondroitin; chondroitin sulfates; carboxymethyl dextran; carboxymethyl chitosan; chitosan; heparin; heparin sulfate; heparin; heparan sulfate; dermatan sulfate; keratan sulfate; carrageenans; chitosan; starch; amylose; amylopectin; poly-N-glucosamine; polymannuronic acid; polyglucuronic acid; and copolymers and mixtures thereof.

10. A method of enhancing hemostasis in an individual in need thereof comprised of applying the composition of claim 1 to at least one bleeding site on the individual.

11. A composition comprised of

(a) a collagen-related peptide of Formula (I):

B-(Z) m -X

wherein

Z is selected from the group consisting of Gly-Pro-J, Pro-J-Gly and J-Gly-Pro;

J is selected from the group consisting of Hyp, fPro, mPro and Pro;

m is an integer selected from 8, 9, 10, 11, 12, 13, 14 or 15; and,

B and X are independently selected from the group consisting of F 5 -Phe, Phe wherein the phenyl ring is mono or disubstituted with fluoro, chloro, bromo, hydroxyl, methyl or CF 3 , Tyr, 3,4-(OH) 2 -Phe, MeO-Tyr, phenylglycine, 2-naphthyl-Ala, 1-naphthyl-Ala, Tip, Cha, Chg, Met, Leu, Ile and Val; and

(b) a substrate,

wherein the composition comprises a plurality of said collagen-related peptides, wherein the collagen-related peptides are present in the form of a plurality of collagen-related peptide trimers, and wherein the collagen-related peptide trimers are homotrimers or heterotrimers.

12. The composition of claim 11 , wherein the substrate is suitable for implantation into a human body.

13. The composition of claim 12 , wherein the substrate is a suture anchor, suture, staple, surgical tack, clip, plate, screw, film; tissue engineering scaffold; foam or powder.

14. The composition of claim 11 , wherein the substrate is comprised of a polymer selected from the group consisting of aliphatic polyesters, poly(amino acids), copoly(ether-esters), polyalkylenes oxalates wherein the alkyl group has from about 1 to about 10 carbon atoms, polyamides, tyrosine derived polycarbonates, poly(iminocarbonates), polyorthoesters, polyoxaesters, polyamidoesters, polyoxyesters containing amine groups, poly(anhydrides), polyphosphazenes, collagen, elastin, gelatin, polysaccharides, and copolymers and blends thereof.

15. The composition of claim 11 , wherein the substrate is comprised of a material selected from the group consisting of cotton, linen, silk, nylon, polyesters, fluoropolymers, polyolefins, polyurethanes and copolymers and combinations thereof.

16. The composition of claim 11 , wherein the substrate is a substrate that is not to be implanted into a human body.

17. The composition of claim 16 , wherein the substrate is a bandage, an adhesive bandage, or a wound dressing.

18. The composition of claim 11 , wherein the collagen-related peptide is present in the composition in an amount, based upon the total surface area of the substrate, from about 0.01 mg/cm 2 to about 1 mg/cm 2 .

19. The composition of claim 11 , wherein the collagen-related peptide is present in the composition in an amount, based upon the total surface area of the substrate, from about 0.1 mg/cm 2 to about 0.5 mg/cm 2 .

20. The composition of claim 11 , wherein the substrate is a foam comprised of a copolymer of epsilon-caprolactone and glycolide.

21. A method of enhancing hemostasis in an individual in need thereof comprised of applying the composition of claim 11 to a bleeding site on the individual.

22. A method of enhancing hemostasis in an individual in need thereof comprised of applying the composition of claim 20 to a bleeding site on the individual.

23. A gel comprised of:

a) a collagen-related peptide of Formula (I):

B-(Z) m -X

wherein

Z is selected from the group consisting of Gly-Pro-J, Pro-J-Gly and J-Gly-Pro;

J is selected from the group consisting of Hyp, fPro, mPro and Pro;

m is an integer selected from 8, 9, 10, 11, 12, 13, 14 or 15; and,

B and X are independently selected from the group consisting of F 5 -Phe, Phe wherein the phenyl ring is mono or disubstituted with fluoro, chloro, bromo, hydroxyl, methyl or CF 3 , Tyr, 3,4-(OH)2-Phe, MeO-Tyr, phenylglycine, 2-naphthyl-Ala, 1-naphthyl-Ala, Trp, Cha, Chg, Met, Leu, Ile and Val; and

b) a gelling agent, wherein the collagen-related peptide is present in the gel in an amount, based upon the total weight of the gel, from about 0.1 mg/ml to about 10 mg/mL

wherein the composition comprises a plurality of said collagen-related peptides, wherein the collagen-related peptides are present in the form of a plurality of collagen-related peptide trimers, and wherein the collagen-related peptide trimers are homotrimers or heterotrimers.

24. A method of enhancing hemostasis in an individual in need thereof comprised of applying the gel of claim 23 to a bleeding site on the individual.

25. A composition comprised of:

a) a collagen-related peptide of Formula (I):

B-(Z) m -X

wherein

Z is selected from the group consisting of Gly-Pro-J, Pro-J-Gly and J-Gly-Pro;

J is selected from the group consisting of Hyp, fPro, mPro and Pro;

m is an integer selected from 8, 9, 10, 11, 12, 13, 14 or 15; and,

B and X are independently selected from the group consisting of F 5 -Phe, Phe wherein the phenyl ring is mono or disubstituted with fluoro, chloro, bromo, hydroxyl, methyl or CF 3 , Tyr, 3,4-(OH) 2 -Phe, MeO-Tyr, phenylglycine, 2-naphthyl-Ala, 1-naphthyl-Ala, Trp, Cha, Chg, Met, Leu, Ile and Val; and

b) at least one excipient.

26. A medical device comprised of the composition of claim 1 .

27. A medical device comprised of the composition of claim 11 .

28. A medical device comprised of the composition of claim 23 .

29. A medical device comprised of the composition of claim 25 .

30. A method of treating bleeding disorders in an individual in need thereof comprising using a collagen-related peptide of Formula (I): B-(Z)mX wherein

Z is selected from the group consisting of Gly-Pro-J, Pro-J-Gly and J-Gly-Pro;

J is selected from the group consisting of Hyp, fPro, mPro and Pro;

m is an integer selected from 8, 9, 10, 11, 12, 13, 14 or 15; and,

B and X are independently selected from the group consisting of F 5 -Phe, Phe wherein the phenyl ring is mono or disubstituted with fluoro, chloro, bromo, hydroxyl, methyl or CF 3 , Tyr, 3,4-(OH) 2 -Phe, MeO-Tyr, phenylglycine, 2-naphthyl-Ala, 1-naphthyl-Ala, Trp, Cha, Chg, Met, Leu, Ile and Val;

in an amount effective for initiating platelet aggregation on a desired site in said individual.

31. A method of diagnosing bleeding disorders in an individual in need thereof comprising

(a) combining a collagen-related peptide of Formula (I):

B-(Z) m -X

wherein

Z is selected from the group consisting of Gly-Pro-J, Pro-J-Gly and J-Gly-Pro;

J is selected from the group consisting of Hyp, fPro, mPro and Pro;

m is an integer selected from 8, 9, 10, 11, 12, 13, 14 or 15; and,

B and X are independently selected from the group consisting of F 5 -Phe, Phe wherein the phenyl ring is mono or disubstituted with fluoro, chloro, bromo, hydroxyl, methyl or CF 3 , Tyr, 3,4-(OH) 2 -Phe, MeO-Tyr, phenylglycine, 2-naphthyl-Ala, 1-naphthyl-Ala, Trp, Cha, Chg, Met, Leu, Ile and Val;

with blood or plasma containing platelets from said individual to form a mixture; then

(b) adding the mixture to a platelet aggregometer in order to evaluate platelet aggregation in said mixture.

32. A composition comprised of:

(a) a collagen-related peptide of Formula (I):

B-(Z) m -X

wherein

Z is selected from the group consisting of Gly-Pro-J, Pro-J-Gly and J-Gly-Pro;

J is selected from the group consisting of Hyp, fPro, mPro and Pro;

m is an integer selected from 8, 9, 10, 11, 12, 13, 14 or 15; and,

B and X are independently selected from the group consisting of F 5 -Phe, Phe wherein the phenyl ring is mono or disubstituted with fluoro, chloro, bromo, hydroxyl, methyl or CF 3 , Tyr, 3,4-(OH) 2 -Phe, MeO-Tyr, phenylglycine, 2-naphthyl-Ala, 1-naphthyl-Ala, Trp, Cha, Chg, Met, Leu, Ile and Val; and

(b) a pharmaceutically active agent.

33. The composition of claim 32 , wherein the pharmaceutically active agent is selected from the group consisting of hemostatics, antiinfectives, analgesics, antiinflammatory agents, and combinations thereof.

34. The composition of claim 33 , wherein the hemostatics are selected from the group consisting of thrombin, fibrinogen, ADP, ATP, calcium, magnesium, TXA 2 , serotonin, epinephrine, platelet factor 4, factor V, factor EI, PAI-1, thrombospondin and combinations thereof.

35. The composition of claim 33 , wherein the antiinfectives are selected from the group consisting of antibodies, antigens, antibiotics, antiviral agents, and combinations thereof.

36. The composition of claim 33 , wherein the anti-inflammatory agent is an antihistamine.

37. A composition comprising a chemically defined three-dimensional polymer matrix supplemented with a collagen-related peptide of Formula (I):

B-(Z) m -X

wherein

Z is selected from the group consisting of Gly-Pro-J, Pro-J-Gly and J-Gly-Pro;

J is selected from the group consisting of Hyp, fPro, mPro and Pro;

m is an integer selected from 8, 9, 10, 11, 12, 13, 14 or 15; and,

B and X are independently selected from the group consisting of F 5 -Phe, Phe wherein the phenyl ring is mono or disubstituted with fluoro, chloro, bromo, hydroxyl, methyl or CF 3 , Tyr, 3,4-(OH) 2 -Phe, MeO-Tyr, phenylglycine, 2-naphthyl-Ala, 1-naphthyl-Ala, Trp, Cha, Chg, Met, Leu, Ile and Val.